Prodia Widyahusada Tbk PT operates in the Medical laboratories sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Prodia Widyahusada Tbk PT with three other
pharmaceutical manufacturers in Asia:
Dr. Lal PathLabs Ltd
sales of 10.57 billion Indian Rupees [US$148.29 million]
of which 100%
INKON Life Technology Co Ltd
(504.02 million Chinese Renmimbi [US$72.10 million]
of which 79%
was Medical services division), and
Medical & Biological Laboratories Company Limited
based in Japan
(7.07 billion Japanese Yen [US$64.71 million]
of which 99%
was Reagent business).
Prodia Widyahusada Tbk PT reported sales of 1.60 trillion Indonesian Rupiahs (US$114.22 million)
December of 2018.
increase of 9.1%
versus 2017, when the company's sales were 1.47 trillion Indonesian Rupiahs.
Sales at Prodia Widyahusada Tbk PT have increased during each of the previous five years
(and since 2013, sales have increased a total of 60%).